First Patient Dosed With INKmune Therapy in Phase 1/2 Trial for mCRPC

1 year ago 60

The phase 1/2 CaRe PC trial evaluating INKmune, a biologic therapy, in male patients with metastatic castration-resistant prostate cancer has dosed its first patient.

1. Homepage
2. Prostate Cancer
3. First Patient Dosed With INKmune Therapy in Phase 1/2 Trial for mCRPC